Across TCGA pan-cancer cohorts, IGHD4-17 RNA differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of IGHD4-17’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where IGHD4-17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types IGHD4-17 is over-expressed in tumor, although a few such as READ show the opposite, repressed pattern.

LUAD, READ, and KIRC are the cancer types where IGHD4-17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGHD4-17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	All	+0.983	.002	5	view →
READ	All	III,IV	−2.245	.009	2	view →
KIRC	All	All	+0.142	.045	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: IGHD4-17 RNA expression & survival · all IGHD4-17 data types